Monica Messina

Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913

Sabina Chiaretti, Monica Messina, Irene Della Starza et al. · Haematologica · 2020 · 83 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Up-front blinatumomab improves MRD clearance and outcome in adult Ph– B-lineage ALL: the GIMEMA LAL2317 phase 2 study

Renato Bassan, Sabina Chiaretti, Irene Della Starza et al. · Blood · 2025 · 33 citations · Full text

Medicine, Oncology, Pathology +10

Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial

Renato Bassan, Sabina Chiaretti, Irene Della Starza et al. · Blood Advances · 2023 · 30 citations · Full text

Medicine, Hematology, Oncology +15

Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial

Sabina Chiaretti, Irene Della Starza, Alessandra Santoro et al. · Blood · 2023 · 27 citations · Full text

Medicine, Hematology, Oncology +17

Comparison between Dasatinib-Blinatumomab Vs Ponatinib-Blinatumomab Chemo-Free Strategy for Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia Patients. Preliminary Results of the Gimema ALLL2820 Trial

Sabina Chiaretti, Matteo Leoncin, Loredana Elia et al. · Blood · 2023 · 16 citations

Medicine, Hematology, Oncology +12